Probing Diseases using Small Molecules

Small molecules are powerful tools to probe biological systems and cure diseases. In the scope of this dissertation, small molecules were applied to study three distinct disease models: cancer, Sedaghatian-type spondylometaphyseal dysplasia (SSMD), and COVID-19. First, encouraged by the recently rep...

Full description

Bibliographic Details
Main Author: Liu, Hengrui
Language:English
Published: 2021
Subjects:
Online Access:https://doi.org/10.7916/d8-26na-1487
id ndltd-columbia.edu-oai-academiccommons.columbia.edu-10.7916-d8-26na-1487
record_format oai_dc
spelling ndltd-columbia.edu-oai-academiccommons.columbia.edu-10.7916-d8-26na-14872021-01-26T05:03:53ZProbing Diseases using Small MoleculesLiu, Hengrui2021ThesesChemistryCOVID-19 (Disease)--TreatmentCancer--TreatmentTherapeuticsSmall molecules are powerful tools to probe biological systems and cure diseases. In the scope of this dissertation, small molecules were applied to study three distinct disease models: cancer, Sedaghatian-type spondylometaphyseal dysplasia (SSMD), and COVID-19. First, encouraged by the recently reported vulnerability of drug-resistant, metastatic cancers to GPX4 (Glutathione Peroxidase 4) inhibition, we examined the basis for nanomolar potency of proof-of-concept GPX4 inhibitors, which revealed an unexpected allosteric binding site. Through hierarchical screening of a lead-optimized compound library, we identified novel small molecules binding to this allosteric site. Second, a homozygous point mutation in the GPX4 gene was identified in three living patients with SSMD. With a structure-based analysis and cell models of the patient-derived variant, we found that the missense variant significantly changed the protein structure and caused substantial loss of enzymatic function. Proposed proof-of-concept treatments were subsequentially validated in patient fibroblasts. Our further structural investigation into the origin of the reduced enzymatic activity revealed a key residue modulating GPX4 enzymatic function. We also found that the variant alters the degradation of GPX4, unveiling the native degradation mechanism of GPX4 protein. Third, driven by the recent urgent need for COVID-19 antiviral therapeutics, we utilized the conservation of 3CL protease substrate-binding pockets across coronaviruses to identify four structurally divergent lead compounds that inhibit SARS-CoV-2 3CL protease. With structure-based optimization, we ultimately identified drug-like compounds with < 10 nM potency for inhibiting the SARS-CoV-2 3CL protease and blocking SARS-CoV-2 replication in human cells.Englishhttps://doi.org/10.7916/d8-26na-1487
collection NDLTD
language English
sources NDLTD
topic Chemistry
COVID-19 (Disease)--Treatment
Cancer--Treatment
Therapeutics
spellingShingle Chemistry
COVID-19 (Disease)--Treatment
Cancer--Treatment
Therapeutics
Liu, Hengrui
Probing Diseases using Small Molecules
description Small molecules are powerful tools to probe biological systems and cure diseases. In the scope of this dissertation, small molecules were applied to study three distinct disease models: cancer, Sedaghatian-type spondylometaphyseal dysplasia (SSMD), and COVID-19. First, encouraged by the recently reported vulnerability of drug-resistant, metastatic cancers to GPX4 (Glutathione Peroxidase 4) inhibition, we examined the basis for nanomolar potency of proof-of-concept GPX4 inhibitors, which revealed an unexpected allosteric binding site. Through hierarchical screening of a lead-optimized compound library, we identified novel small molecules binding to this allosteric site. Second, a homozygous point mutation in the GPX4 gene was identified in three living patients with SSMD. With a structure-based analysis and cell models of the patient-derived variant, we found that the missense variant significantly changed the protein structure and caused substantial loss of enzymatic function. Proposed proof-of-concept treatments were subsequentially validated in patient fibroblasts. Our further structural investigation into the origin of the reduced enzymatic activity revealed a key residue modulating GPX4 enzymatic function. We also found that the variant alters the degradation of GPX4, unveiling the native degradation mechanism of GPX4 protein. Third, driven by the recent urgent need for COVID-19 antiviral therapeutics, we utilized the conservation of 3CL protease substrate-binding pockets across coronaviruses to identify four structurally divergent lead compounds that inhibit SARS-CoV-2 3CL protease. With structure-based optimization, we ultimately identified drug-like compounds with < 10 nM potency for inhibiting the SARS-CoV-2 3CL protease and blocking SARS-CoV-2 replication in human cells.
author Liu, Hengrui
author_facet Liu, Hengrui
author_sort Liu, Hengrui
title Probing Diseases using Small Molecules
title_short Probing Diseases using Small Molecules
title_full Probing Diseases using Small Molecules
title_fullStr Probing Diseases using Small Molecules
title_full_unstemmed Probing Diseases using Small Molecules
title_sort probing diseases using small molecules
publishDate 2021
url https://doi.org/10.7916/d8-26na-1487
work_keys_str_mv AT liuhengrui probingdiseasesusingsmallmolecules
_version_ 1719374274611904512